PCA-PAM50 Improves Consistency Between Breast Cancer Intrinsic and Clinical Subtyping Reclassifying a Subset of Luminal a Tumors as Luminal B

Scientific Reports - United Kingdom
doi 10.1038/s41598-019-44339-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Luminal-B Breast Cancer and Novel Therapeutic Targets

Breast Cancer Research
Cancer ResearchOncology
2011English

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance With Standard Clinical Molecular Markers

BMC Medical Genomics
Genetics
2012English

Basal Markers and Prognosis in Luminal Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2017English

Comparison of Clinical Outcomes Between Luminal Invasive Ductal Carcinoma and Luminal Invasive Lobular Carcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Illuminating Luminal B: QSOX1 as a Subtype-Specific Biomarker

Breast Cancer Research
Cancer ResearchOncology
2013English

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

Annals of Surgical Oncology
OncologySurgery
2016English

PDEF Promotes Luminal Differentiation and Acts as a Survival Factor for ER-Positive Breast Cancer Cells

Cancer Cell
Cancer ResearchOncologyCell Biology
2013English

Neuroendocrine Tumors of the Luminal Gastrointestinal Tract

Archives of Pathology and Laboratory Medicine
MedicineForensic MedicinePathologyMedical Laboratory Technology
2015English

Cost-Effectiveness of Lymphadenectomy in Patients With Early Breast Cancer Luminal Type A

Tumors of female reproductive system
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy